InflaRx management commentary cites lower R&D spending as driver of narrower nine-month loss through September 2026
IFRX•InflaRx reported a nine-month net loss of EUR 18.68 million through September 30, 2026, compared with EUR 34.99 million a year earlier. Operating cash outflows narrowed to EUR 14 million from EUR 30.61 million.
1. Loss narrowed
InflaRx reported a net loss of EUR 18.68 million for the nine months through September 30, 2026, versus EUR 34.99 million in the same period a year earlier. Research and development expenses fell to EUR 11.94 million, reflecting lower external-service costs, reduced share-based compensation and prior-year program wind-down provisions.
2. Costs and cash
Sales and marketing expenses declined by EUR 3.37 million, primarily reflecting the discontinuation of active GOHIBIC sales activities in December 2025. Operating cash outflows narrowed to EUR 14 million from EUR 30.61 million a year earlier.
3. Available funds
InflaRx had EUR 153.3 million in available funds, including EUR 119.3 million in net proceeds from its May 2026 ordinary-share offering.
